The VCX™ Discovery Platform is a pioneering high-throughput screening solution designed to assess new drug candidates, spanning chemical, botanical, or biological entities. Through personalized consultations with our clients, we strategically identify and target relevant diseases of interest, streamlining the drug discovery process.

By significantly reducing screening time and pinpointing overlooked candidate compounds, the VCX™ Discovery Platform not only accelerates breakthrough innovations but also generates substantial cost savings, amounting to millions of dollars. Our advanced technology revolutionizes the drug development landscape, driving the future of healthcare and delivering life-changing solutions to patients worldwide.

THE ADAPTABILITY OF THE PLATFORM

The adaptability of the platform is based on personalized consultation with clients to identify disease target of interest, optimized cell based models of pathophysiology, targeted mixing and matching of key cellular assays to define therapeutic benefit, and ultimate screening and candidate identification based on defined machine learning analysis based on proprietary in house validated data on reference drug targets. Additional scale and disease/target validation to screening is offered by enhanced testing in C. elegans, a model organism, for a variety of processes.

SCALABLE SYSTEM THAT SAVES MONEY AND TIME

The VCX™ Discovery Platform is a scalable system that saves millions of dollars in the drug discovery process consumed by sup-prime models and assays, time to screen, and poorly identified candidate compounds. The VCX Platform de-risks the discovery and development process by providing a means of assessing the therapeutic potential of hundreds of compounds over a short period of time, generating data in months, not years.

AVAILABLE MODELS

With the completion of the development of the VCX Discovery Platform and filing of IP, Verséa Discovery is now begin screening hemp-derived and pharmaceutical compounds to build a pipeline of New Chemical Entities (NCEs) and Botanical Rx drug candidates using standard as well as personalized based in vitro model systems. Areas of interest and available models at Verséa Discovery include: